Rewind Therapeutics develops first-in-class therapeutics that promote remyelination to restore the myelin sheath in patients with neurological diseases such as multiple sclerosis and optic neuritis. By repairing this protective nerve covering, the company aims to halt disease progression and improve patient outcomes.
Funding
$31.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Neurological diseases like multiple sclerosis, optic neuritis, and nerve injuries are characterized by the loss of the myelin sheath, which protects and nurtures nerves. This demyelination disrupts nerve function, leading to disease progression and debilitating symptoms. Current treatments often fail to adequately address the underlying myelin damage and restore nerve function.
Solution
Rewind Therapeutics is developing first-in-class therapeutics designed to re-initiate the process of remyelination in patients suffering from demyelinating diseases. Their approach focuses on repairing or reinstalling the myelin sheath, a crucial factor for halting or even curing these diseases. By promoting remyelination, Rewind aims to restore nerve function, halt disease progression, and improve patient outcomes. The company leverages extensive research and development expertise and a strong patent estate to develop novel remyelination therapeutics.
Target Audience
The primary target audience includes patients suffering from neurological diseases characterized by demyelination, as well as clinicians and researchers focused on developing new treatments for these conditions.
Features
- Focus on promoting remyelination to restore the myelin sheath in neurological diseases.
- Development of first-in-class therapeutics targeting the underlying mechanisms of demyelination.
- Strong patent estate protecting novel remyelination approaches.
- Addressing diseases such as multiple sclerosis, optic neuritis, and nerve injuries.